Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 903 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Interaction Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

AV650 Drug-Drug Interaction Study

NCT00456560
View directory record Official record
Conditions
Healthy
Interventions
AV650, Fluvoxamine, Paroxetine
Drug
Lead sponsor
Avigen
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2007 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Raltegravir And UK-453,061

NCT00784420
View directory record Official record
Conditions
Healthy Volunteers
Interventions
UK-453,061, Raltegravir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2008 · Synced Sep 2, 2026, 7:01 AM EDT
Suspended Phase 2Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression

NCT02988076
View directory record Official record
Conditions
Depression
Interventions
PEER Interactive Report
Device
Lead sponsor
MYnd Analytics
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

NCT01487460
View directory record Official record
Conditions
Dyslipidemia, Healthy Volunteers
Interventions
TAP311
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

NCT01458054
View directory record Official record
Conditions
Hepatitis C
Interventions
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

NCT02824042
View directory record Official record
Conditions
Medical Oncology
Interventions
Anetumab ravtansine (BAY94-9343), Itraconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Santa Monica, California • Detroit, Michigan • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

NCT00000941
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional

Cocaine-Methylphendidate Interaction Study - 4

NCT00015067
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers

NCT01303445
View directory record Official record
Conditions
Healthy
Interventions
Aggrenox alone, Aggrenox and omeprazole, Omeprazole alone
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 2, 2026, 7:01 AM EDT
Withdrawn Phase 1 Interventional

A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer

NCT00534807
View directory record Official record
Conditions
Cancer
Interventions
Vinflunine, Rifampin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

NCT01209065
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Fosamprenavir, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

NCT05541471
View directory record Official record
Conditions
Pain
Interventions
VX-548, Midazolam, Digoxin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 2, 2026, 7:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating Baby Behavior and Family Technology Use Study

NCT05781100
View directory record Official record
Conditions
Mobile Phone Use, Mother-Infant Interaction, Infant Development, Self-Regulation, Emotion, Self-Regulation
Interventions
Technology Use during Feeding Conditions
Behavioral
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
Not listed
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional

Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout

NCT02252835
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Arhalofenate, Febuxostat, Colchicine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

NCT04809818
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
LT3001 drug product, Placebo, Aspirin, Clopidogrel, Apixaban, Dabigatran
Drug
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

NCT02617810
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Midazolam, Warfarin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

NCT00802074
View directory record Official record
Conditions
Healthy
Interventions
Raltegravir, Fosamprenavir, Ritonavir
Drug
Lead sponsor
Garden State Infectious Disease Associates, PA
Other
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Levoketoconazole and Metformin

NCT03880825
View directory record Official record
Conditions
Healthy Subjects
Interventions
Metformin 500 mg Oral Tablet, Levoketoconazole 150 - 600 mg (BID)
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

NCT06740825
View directory record Official record
Conditions
Healthy Subjects
Interventions
Quizartinib, Rufinamide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

NCT01536249
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Cimetidine plus Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CP-690,550 and Midazolam Drug-Drug Interaction Study

NCT00902460
View directory record Official record
Conditions
Healthy Volunteer
Interventions
midazolam; CP-690,550 + midazolam, CP-690,550 + midazolam; midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin

NCT01422382
View directory record Official record
Conditions
Healthy
Interventions
Pitavastatin (NK-104), Diltiazem (Cardizem LA) 240 mg QD
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 2, 2026, 7:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118

NCT01533870
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
NKTR-118, Rifampin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 2, 2026, 7:01 AM EDT